Acute Pancreatitis – Caerulein-Induced Model (Upcoming)
The caerulein-induced pancreatitis model is a well-established method for inducing acute pancreatic inflammation in mice. Caerulein, a cholecystokinin analog, is administered via repeated intraperitoneal injections, leading to acinar cell hyperstimulation, edema, neutrophil infiltration, and elevated pancreatic enzymes (amylase, lipase).
Planned Features:
- Induction of acute pancreatitis via intraperitoneal caerulein injections
- Rapid onset of inflammation and edema in the pancreas
- Elevated serum amylase and lipase levels
- Histological assessment of tissue damage and neutrophil infiltration
- Suitable for evaluating anti-inflammatory and cytokine-targeting therapies
- Compatible with flow cytometry and cytokine profiling of pancreas and systemic compartments
Model Readouts and Capabilities (Under Development)
Redoxis will support pancreatitis models with a comprehensive set of analytical tools:
- Histopathology of pancreatic tissue (edema, necrosis, infiltration)
- Serum biomarker analysis (amylase, lipase, IL-6, TNF-α)
- Flow cytometry of infiltrating immune cells in pancreas and spleen
- Ex vivo stimulation assays from draining lymph nodes
- Cytokine profiling via Luminex or ELISA
- Optional extensions to study systemic inflammation or progression to chronic disease
Our pancreatitis models will complement Redoxis’ existing portfolio of inflammation-focused in vivo systems and are designed for early-stage evaluation of therapeutic agents targeting cytokine signaling, immune activation, and tissue protection.
Please contact us if you are interested in being an early user of these models or to discuss study design options as they become available.
Additional services
Pharmacokinetics (PK) and PK/PD Services
At Redoxis, we support the early development of drug candidates with comprehensive pharmacokinetic (PK) and pharmacodynamic (PD) services, enabling a better understanding of compound exposure, distribution, and efficacy in relevant preclinical models.
Our PK and PK/PD studies are integrated with in vivo efficacy models, allowing for streamlined assessment of drug behavior and therapeutic effect. We offer tailored study designs to suit different drug modalities, including small molecules, biologics, mRNA therapies, and cell and gene therapies.
To support these studies, Redoxis collaborates with RG Discovery, a trusted partner with extensive experience in bioanalytical method development and sample analysis. Through this collaboration, we ensure high-quality data for:
- Plasma concentration measurements
- Tissue distribution
- PK profiling (single or multiple dose)
- Dose-response and exposure-response analysis
- Correlation of PK data with efficacy (PK/PD modeling)
Together with RG Discovery, we provide a seamless workflow from sample collection to validated bioanalytical results, enabling confident decision-making in your preclinical program.
Whether you are looking for a stand-alone PK study or wish to integrate PK/PD readouts into our in vivo disease models, we are here to support your development needs with flexibility and scientific expertise.
In Vivo Characterization of ATMPs
Advanced Therapy Medicinal Products (ATMPs), including gene therapies, cell therapies, and mRNA-based treatments, require thorough preclinical characterization to understand biodistribution, persistence, and immune responses in vivo. At Redoxis, we offer tailored in vivo studies to support the mechanistic understanding and safety profiling of ATMPs in relevant immunological settings.
With extensive experience working with viral vectors, engineered immune cells, and nucleic acid-based modalities, we help developers address key translational questions through customized in vivo protocols. Our in vivo work is supported by a certified Biosafety Level 2 (BSL-2) laboratory, ensuring safe and compliant handling of viral vectors and other ATMP components.
Our capabilities include:
- Biodistribution studies using reporter systems, qPCR, or cell labeling
- Persistence and expansion monitoring of engineered cells or vectors over time
- Immunogenicity assessment and host immune response profiling
- Innate and adaptive immune activation, including cytokine analysis and flow cytometry
- Tissue-specific responses evaluated by histology, flow cytometry, or cytokine release
These studies are designed to support product characterization, vector optimization, and comparability testing, and can be integrated with ex vivo or in vitro assays for a comprehensive data package.
Redoxis offers the flexibility, scientific rigor, and immunological expertise needed to advance ATMPs toward clinical development with confidence.
Contact us
Nina Woodworth
COO